Beneft of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients with Versus Without Diabetes Mellitus Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effcacy International Trial)

Circulation

Volumn 137, Issue 15, 2018, Pages 1571-1582

  Giugliano, Robert P ^a   Cannon, Christopher P ^a   Blazing, Michael A ^b   Nicolau, José C ^c   Corbalán, Ramón ^d   Pinar, Jindrich ^e   Park, Jeong Gun ^a   White, Jennifer A ^b   Bohula, Erin A ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Centro Médico Clínica   (Chile)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

acute coronary syndromes; diabetes mellitus; ezetimibe; lipids

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; BIOLOGICAL MARKER; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; BLOOD; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; DYSLIPIDEMIA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TIME FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; BIOMARKERS; CHOLESTEROL, LDL; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85046976807     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.030950     Document Type: Article

References (34)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemio-logical studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31-40. doi: 10.1016/S0140-6736(11)60679-X.
2. World Health Organization. Diabetes Fact Sheet. 2017. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed October 27, 2017.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
4. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon C P, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765-775. doi: 10.1001/jama.298.7.765.
5. Standards of Medical Care in Diabetes-2017: Summary of revisions. Diabetes Care. 2017;40:S4?S5.
6. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C; Cholesterol Treatment Trialists' (CTT) Collaborators. Effcacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125. doi: 10.1016/S0140-6736(08)60104-X.
7. Morrone D, Weintraub WS, Toth P P, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM. Lipid-altering effcacy of ezetimibe plus statin and statin monotherapy and identifcation of factors associ-ated with treatment response: a pooled analysis of over 21, 000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251-261. doi: 10.1016/j.atherosclerosis.2012.02.016.
8. Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013;100:46-52. doi: 10.1016/j.diabres.2012.12.026.
9. Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, Tershakovec AM. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. J Clin Lipidol. 2008;2:19-24. doi: 10.1016/j.jacl.2007.12.004.
10. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cho-lesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220-1226. doi: 10.2337/dc05-2465.
11. Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering benefcial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006;27:2323-2329. doi: 10.1093/eurheartj/ehl220.
12. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696. doi: 10.1016/S0140-6736(04)16895-5.
13. Standards of Medical Care in Diabetes-2015. Diabetes Care. 2015;38(Suppl 1): 1-94.
14. Cannon C P, Blazing MA, Giugliano R P, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397. doi: 10.1056/NEJMoa1410489.
15. Cannon CP, Giugliano R P, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM; IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Effcacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826-832. doi: 10.1016/j.ahj.2008.07.023.
16. Bohula EA, Giugliano RP, Cannon C P, Zhou J, Murphy SA, White JA, Ter-shakovec AM, Blazing MA, Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132:1224-1233. doi: 10.1161/CIRCULATIONAHA.115.018381.
17. Bohula EA, Bonaca M P, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA. Atherothrombotic risk stratifcation and the effcacy and safety of vorapaxar in patients with stable ischemic heart disease and previous myocardial infarction. Circulation. 2016;134:304-313. doi: 10.1161/CIRCULATIONAHA.115.019861.
18. Bohula EA, Morrow DA, Giugliano R P, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon C P, Braunwald E. Atherothrombotic risk stratifcation and ezetimibe for secondary prevention. J Am Coll Cardiol. 2017;69:911-921. doi: 10.1016/j.jacc.2016.11.070.
19. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R; Cholesterol Treatment Trialists' (CTT) Collaboration. Effcacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681. doi: 10.1016/S0140-6736(10)61350-5.
20. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zi-dan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol. 2008;65:637-645. doi: 10.1111/j.1365-2125.2007.03080.x.
21. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H; PRECISE-IVUS Investigators. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the Mul-ticenter Randomized Controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495-507. doi: 10.1016/j.jacc.2015.05.065.
22. Muñoz-Pacheco P, Ortega-Hernández A, Miana M, Cachofeiro V, Fernán-dez-Cruz A, Gómez-Garre D. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism. Pharmacol Res. 2012;66:536-543. doi: 10.1016/j.phrs.2012.09.005.
23. Sternberg Z, Chichelli T, Sternberg D, Hojnacki D, Drake A, Liu S, Hu Q, Munschauer F. Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hy-percholesterolemic subjects. Atherosclerosis. 2013;231:411-420. doi: 10.1016/j.atherosclerosis.2013.09.031.
24. Qin L, Yang YB, Yang YX, Gong YZ, Li XL, Li GY, Luo HD, Xie XJ, Zheng XL, Liao D F. Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway. J Pharmacol Sci. 2014;125:283-291.
25. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 infammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357-1361. doi: 10.1038/nature08938.
26. Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ. Cholesterol crystals associate with coronary plaque vulnerability in vivo. J Am Coll Cardiol. 2015;65:630-632. doi: 10.1016/j.jacc.2014.11.039.
27. Roff M, Chew D P, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001;104:2767-2771.
28. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators. Greater clinical beneft of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118:1626-1636. doi: 10.1161/CIRCULATIONAHA.108.791061.
29. Cavender MA, Scirica BM, Bonaca M P, Angiolillo DJ, Dalby AJ, Dell-borg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: fndings from the thrombin receptor antagonist in secondary prevention of atherothrombotic isch-emic events-TIMI 50 trial. Circulation. 2015;131:1047-1053. doi: 10.1161/CIRCULATIONAHA.114.013774.
30. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey R F, Stevens SR, Wallentin L; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Eur Heart J. 2010;31:3006-3016. doi: 10.1093/eurheartj/ehq325.
31. Bach RG, Cannon CP, Giugliano R P, White JA, Lokhnygina Y, Tershakovec AM, Musliner TA, Braunwald E and Blazing MA. Increasing age and the beneft from higher-intensity lipid-lowering with ezetimibe/simvastatin vs. simvastatin alone: results from the IMPROVE-IT trial. Circulation. 2015;132:A16708.
32. Eisen A, Cannon C P, Blazing MA, Bohula EA, Park JG, Murphy SA, White JA, Giugliano RP, Braunwald E; IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Effcacy International Trial) Investigators. The beneft of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016;37:3576-3584. doi: 10.1093/eurheartj/ehw377.
33. Bohula EA, Wiviott SD, Giugliano R P, Blazing MA, Park J-G, Murphy SA, White JA, Mach F, Van de Werf FJ, Dalby AJ, White HD, Tershakovec AM, Cannon C P, Braunwald E. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effcacy International Trial). Circulation. 2017;136:2440-2450. doi: 10.1161/CIRCULA-TIONAHA.117.029095.
34. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(suppl 2):1-87. doi: 10.4158/EP171764.APPGL.